Sanjay Srivastava

Sanjay Srivastava, Ph.D., is a Managing Director in Accenture’s Life Sciences Strategy & Consulting practice, leading Cell & Gene Therapy CoE and practice. Sanjay has broad and deep expertise in the underpinning science and business challenges in developing and launching both in-vivo and ex-vivo C>s. He has global expertise in R&D, supply chain, manufacturing, and commercial operations. He is active in the industry, driving harmonization and simplicity in C> practices and has presented his insights at various CGT conferences.


  • Shaping A System That Enables Patients To Access High-Cost Cell & Gene Therapies

    The health and life sciences industry needs to create an effective financial system to support the complex new payment structures being adopted for cell and gene therapies.

  • Scaling Cell and Gene Therapy Manufacturing Operations

    Manufacturing autologous cell therapy products faces few key complications, which is typically why CAR-T manufacturing runs at two or three sigma operations.

  • Part 2: Cell And Gene Therapy Is Transforming Healthcare

    Healthcare sector players are neither adequately equipped nor strategically placed near patients to accommodate the anticipated volume of clinical trials to evaluate cell and gene therapies (CGT) in development. While the industry is adjusting and deploying the required capabilities, the transformation is evolving and incomplete. Real change requires rethinking how current sector players are adopting and how they will operate in the future.

  • How Cell And Gene Therapy Is Transforming Healthcare

    But overcoming challenges is key to meeting CGT promise.

  • Establishing And Maintaining A Treatment Network For Your Cell And Gene Therapy Product

    Delivering cell and gene therapies is an expensive and highly complex process, and there are a number of critical metrics that manufacturers should consider when selecting treatment sites. Subsequent activities — preparing sites to receive and initiate therapy, and managing site training and ongoing certification — can be equally, if not more, challenging.

  • Transforming Next-Gen Therapy Supply Chains Into Patient-Connected Value Chains

    Cell, gene, and other emerging therapies are distinctly different from traditional biopharma products. Every lot is for a named patient or small population of patients, and that lot drives direct uplift on the bottom line. Traditional supply chain management does not necessarily create patient value in emerging therapy value chains. Operations should be the backbone of a distribution model that delivers these products efficiently and effectively over the last few yards.